Tau Protein News and Research

RSS

Tau proteins are microtubule-associated proteins found in neurons in the brain.

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

The American Academy of Neurology has awarded the 2011 Potamkin Prize to Dennis Dickson, M.D., a neuropathologist at Mayo Clinic in Florida and the Robert E. Jacoby Professor for Alzheimer's Disease Research.

3 Mar 2011

AAN honors three researchers with 2011 Potamkin Prize for dementia study

The American Academy of Neurology is awarding its 2011 Potamkin Prize to three researchers for their work in dementia. Dennis Dickson, MD, with the Mayo Clinic in Jacksonville, Florida, Eva Maria Mandelkow, MD, PhD, and Eckhard Mandelkow, PhD, both of the Max-Planck-Unit for Structural Molecular Biology in Hamburg, Germany, will receive the Award during the AAN's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

17 Feb 2011

Brain enzyme blocks accumulation of tau proteins, slows down progression of neural degeneration

Increasing puromycin-sensitive aminopeptidase, the most abundant brain peptidase in mammals, slowed the damaging accumulation of tau proteins that are toxic to nerve cells and eventually lead to the neurofibrillary tangles, a major pathological hallmark of Alzheimer's disease and other forms of dementia, according to a study published online in the journal, Human Molecular Genetics.

17 Feb 2011

Deactivation of tau gene may help reverse memory loss in Alzheimer disease

Amyloid-beta and tau protein deposits in the brain are characteristic features of Alzheimer disease. The effect on the hippocampus, the area of the brain that plays a central role in learning and memory, is particularly severe. However, it appears that the toxic effect of tau protein is largely eliminated when the corresponding tau gene is switched off.

16 Feb 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

Chaperone protein study could lead to effective therapies for Alzheimer's, neurological disorders

Dynamic regulation of the chaperone protein Hsp27 was required to get rid of abnormally accumulating tau in the brains of mice genetically modified to develop the memory-choking tau tangles associated with Alzheimer's disease, a University of South Florida-led study found.

4 Dec 2010

Diabetes drug may counteract against Alzheimer's disease: Research

Metformin, a drug used in type 2-diabetes might have the potential to also act against Alzheimer's disease. This has been shown in a study from scientists of the German Center for Neurodegenerative Diseases (DZNE), the University of Dundee and the Max-Planck-Institute for Molecular Genetics.

24 Nov 2010

Researchers find clue behind dementia development

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.

18 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

Microglial inflammation promotes MAPT pathologies

Cells that help to protect the central nervous system may also contribute to pathological changes in the brain. New research, published by Cell Press in the October 7th issue of the journal Neuron, provides mechanistic insight into a link between the immune system and neurodegenerative disorders like Alzheimer's disease that are associated with abnormal accumulation of tau protein.

7 Oct 2010

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Tasly Pharmaceutical Co., Ltd. and ProteoTech, Inc. today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate Alzheimer's disease.

5 Oct 2010

Researches discover reducing tau protein level can prevent Αβ protein transport in Alzheimer’s disease

Amyloid beta (Αβ) proteins, widely thought to cause Alzheimer's disease (AD), block the transport of vital cargoes inside brain cells. Scientists at the Gladstone Institute of Neurological Disease (GIND) have discovered that reducing the level of another protein, tau, can prevent Aβ from causing such traffic jams.

10 Sep 2010

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

Brain trauma in sports associated with motor neuron disease, researchers find

The Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine and Department of Veterans Affairs announced today that they have provided the first pathological evidence that repetitive head trauma experienced in collision sports is associated with motor neuron disease, a neurological condition that affects voluntary muscle movements.

18 Aug 2010

Alzheimer’s disease can now be predicted with 100% accuracy: Study

In a new development, Alzheimer's disease can now be predicted with up to 100 percent accuracy several years before its onset using three special marker proteins present in the spinal fluids. The study was published in the American Medical Association's Archives of Neurology.

9 Aug 2010

Detection of Alzheimer's before symptoms occur

Research is on to detect the dreaded Alzheimer's disease even before any symptoms occur. In a newly proposed diagnostic criteria developed by experts from the National Institute on Aging and the Alzheimer's Association three stages of the disease viz. pre-clinical Alzheimer's, mild cognitive impairment and Alzheimer's dementia are described.

4 Aug 2010

Major breakthrough in Alzheimer's disease research

Researchers from the University of Sydney's Alzheimer's and Parkinson's Disease Laboratory have achieved a major breakthrough by finding the causes of Alzheimer's disease at a cellular level and thereby identifying a potential therapy as a result.

23 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century – Alzheimer's disease – at the Alzheimer's Association's 2010 International Conference on Alzheimer's Disease in Honolulu.

15 Jul 2010

AD may lead to increased risk of comorbid conditions, research shows

Pfizer Inc., together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 from two podium and four poster presentations.

14 Jul 2010